Emcure to Expand the Use of Poviztra® for MASH IndicationFollowing CDSCO Approval
New Delhi : Emcure Pharmaceuticals Limited today announced that Poviztra®, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of!-->…